Generation of tumor neoantigens by RNA splicing perturbation

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Cancer immunotherapy has advanced significantly, but a major hurdle is the scarcity of tumor-specific neoantigens.
• Alternative mRNA splicing presents a promising, largely untapped source for novel neoantigen discovery in various cancers.
• Splicing factor mutations and aberrant splicing patterns are common in tumors and critical for neoantigen generation.

Purpose of the Study:

• To review and discuss advancements in splicing modulation techniques for cancer immunotherapy.
• To highlight the potential of targeting mRNA splicing for enhancing anti-tumor immune responses.
• To explore the clinical applicability of splicing-based neoantigen strategies.

Main Methods:

• Overview of small-molecule drugs targeting splicing.
• Discussion of splice-switching antisense oligonucleotides (SSOs) and small interfering RNAs (siRNAs).
• Exploration of CRISPR technology, nonsense-mediated RNA decay (NMD) inhibition, and decoy approaches for splicing modulation.

Main Results:

• Splicing modulation strategies can be adapted to generate a diverse repertoire of tumor-specific neoantigens.
• These approaches have the potential to overcome the limitations of current neoantigen identification methods.
• Targeting splicing pathways can significantly enhance anti-tumor immune responses.

Conclusions:

• Splicing modulation represents a powerful strategy to expand the scope of cancer immunotherapy.
• These novel approaches hold promise for developing more effective and personalized cancer treatments.
• Further clinical investigation of splicing-based immunotherapies is warranted to broaden their efficacy.